logo.jpg
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
August 03, 2023 01:00 ET | Addex Therapeutics
Discovery collaboration on track to deliver clinical candidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3, 2023 - Addex...
logo.jpg
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
July 24, 2023 01:00 ET | Addex Therapeutics
Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva,...
logo.jpg
Addex Increases Issued Share Capital to Create Treasury Shares
June 15, 2023 01:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 15, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
logo.jpg
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 01, 2023 01:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 1, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
logo.jpg
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
May 18, 2023 01:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
logo.jpg
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
May 11, 2023 01:00 ET | Addex Therapeutics
ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc...
logo.jpg
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
May 10, 2023 01:00 ET | Addex Therapeutics
Cohort 1 progressing through Part 2Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a...
logo.jpg
Addex Convenes Annual General Meeting 2023
May 05, 2023 01:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
logo.jpg
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
May 04, 2023 01:00 ET | Addex Therapeutics
Geneva, Switzerland, May 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
logo.jpg
Addex Completes $5.0 Million Equity Financing
April 05, 2023 01:00 ET | Addex Therapeutics
Proceeds to advance allosteric modulator therapeutic pipeline Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 5, 2023 – Addex Therapeutics Ltd (SIX: ADXN and...